London, UK, 3 February 2026 - Persica Pharmaceuticals Limited (Persica), a clinical stage biotechnology company developing a transformative treatment for chronic Low Back Pain (cLBP), today announces ...
The PP353 clinical trial met the primary endpoint and demonstrated statistically significant, clinically meaningful and durable reduction in pain and disability in patients with chronic Low Back Pain ...
In this 2-year follow-up study, we found a significant positive association between the change in the extent of M1 and change in ODI. We also found a positive association between the change in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results